Source comparison
Does BPC-157 Help Scar Healing: Comparison of Approaches
BPC-157 (10 mcg/kg daily, days 3–14 post-injury) VEGF upregulation + FAK activation → organized collagen deposition 30–40% reduction in scar width in rat tendon/skin models Subcutaneous injection or topical hydrogel No human trials; dosing extrapolation from a
This comparison does not assign a generated winner or score.
- BPC-157 (10 mcg/kg daily, days 3–14 post-injury)
- VEGF upregulation + FAK activation → organized collagen deposition
- 30–40% reduction in scar width in rat tendon/skin models
- Subcutaneous injection or topical hydrogel
- No human trials; dosing extrapolation from animal data; not FDA-approved
- Strongest preclinical mechanistic evidence for structural scar reduction. Pending human validation
- Silicone gel sheeting (12+ hours/day for 8–12 weeks)
- Occlusion → hydration + reduced tension on healing tissue
- 30–50% improvement in Vancouver Scar Scale scores in human RCTs
- Topical adhesive sheet
- Requires months of consistent use; cosmetic improvement more than structural change
- Gold standard for existing scar management. Minimal risk, established efficacy
- Intralesional corticosteroid (triamcinolone 10–40 mg/mL)
- Suppression of fibroblast activity + collagen synthesis inhibition
- 50–70% reduction in keloid volume over 3–6 months
- Injection directly into hypertrophic scar tissue
- High recurrence rate (40–50%); skin atrophy risk; works on formed scars, not acute wounds
- Effective for keloids/hypertrophic scars after formation. Not a preventive strategy
- Vitamin E topical (applied daily during healing)
- Antioxidant effects theoretically reduce inflammation
- No significant difference vs placebo in RCTs; 30% contact dermatitis rate
- Topical oil or cream
- Weak evidence; high irritation rate in healing wounds
- Not recommended. Contact dermatitis risk outweighs unproven benefit
- Platelet-rich plasma (PRP) injection (1–3 sessions)
- Growth factor delivery (PDGF, TGF-β, VEGF) from concentrated autologous platelets
- Mixed results. Some studies show 20–30% scar width reduction, others show no difference
- Injection into wound bed or scar tissue
- Variable platelet concentration between preparations; expensive; results inconsistent
- Promising but inconsistent. Preparation standardization needed